CXCL2 and Alzheimer disease: At the molecular level, Dex-mediated reductions in CXCL2, iNOS, and SPHK1 further support its ability to restrain microglial activation and cytokine-driven neurotoxicity in AD, offering a mechanistic explanation for the dose-dependent neuroprotection observed in CA1.